MA52742A - Anticorps bispécifiques dll3-cd3 - Google Patents

Anticorps bispécifiques dll3-cd3

Info

Publication number
MA52742A
MA52742A MA052742A MA52742A MA52742A MA 52742 A MA52742 A MA 52742A MA 052742 A MA052742 A MA 052742A MA 52742 A MA52742 A MA 52742A MA 52742 A MA52742 A MA 52742A
Authority
MA
Morocco
Prior art keywords
dll3
bispecific antibodies
bispecific
antibodies
antibodies dll3
Prior art date
Application number
MA052742A
Other languages
English (en)
Other versions
MA52742B1 (fr
Inventor
Paul Adam
Michael Dziegelewski
Rajkumar Ganesan
Philip Nicholas Gorman
Pankaj Gupta
Priyanka Gupta
Susanne Hipp
Justin Scheer
Vladimir H Voynov
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA52742A publication Critical patent/MA52742A/fr
Publication of MA52742B1 publication Critical patent/MA52742B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
MA52742A 2018-06-09 2019-06-07 Anticorps bispécifiques dll3-cd3 MA52742B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18176889 2018-06-09
EP18176888 2018-06-09
EP19159321 2019-02-26
EP19728454.0A EP3802598B1 (fr) 2018-06-09 2019-06-07 Protéines de liaison dll3/cd3 pour le traitement du cancer
PCT/EP2019/064942 WO2019234220A1 (fr) 2018-06-09 2019-06-07 Anticorps bispécifiques dll3-cd3

Publications (2)

Publication Number Publication Date
MA52742A true MA52742A (fr) 2021-04-14
MA52742B1 MA52742B1 (fr) 2025-03-28

Family

ID=66752128

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52742A MA52742B1 (fr) 2018-06-09 2019-06-07 Anticorps bispécifiques dll3-cd3

Country Status (31)

Country Link
US (3) US11332541B2 (fr)
EP (2) EP3802598B1 (fr)
JP (2) JP7133043B2 (fr)
CN (7) CN120131936A (fr)
AU (1) AU2019280900B2 (fr)
BR (1) BR112020022898A2 (fr)
CA (1) CA3099956A1 (fr)
CL (1) CL2020003105A1 (fr)
CO (1) CO2020015172A2 (fr)
CR (1) CR20200601A (fr)
DK (1) DK3802598T3 (fr)
EC (1) ECSP20084864A (fr)
ES (1) ES3021463T3 (fr)
FI (1) FI3802598T3 (fr)
HR (1) HRP20250443T1 (fr)
HU (1) HUE071620T2 (fr)
IL (1) IL279235B1 (fr)
JO (1) JOP20200313A1 (fr)
LT (1) LT3802598T (fr)
MA (1) MA52742B1 (fr)
MX (1) MX2020013348A (fr)
MY (1) MY199655A (fr)
PE (1) PE20210321A1 (fr)
PH (1) PH12020552080A1 (fr)
PL (1) PL3802598T3 (fr)
RS (1) RS66693B1 (fr)
SA (1) SA520420748B1 (fr)
SG (1) SG11202011134XA (fr)
SI (1) SI3802598T1 (fr)
TW (1) TWI848953B (fr)
WO (1) WO2019234220A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
EP3732195A4 (fr) * 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique induisant une cytotoxicité
WO2019217145A1 (fr) 2018-05-08 2019-11-14 Phanes Therapeutics, Inc. Anticorps anti-dll3 et leurs utilisations
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN113260634A (zh) 2018-09-28 2021-08-13 中外制药株式会社 包含改变的抗体可变区的抗原结合分子
EP3870222A4 (fr) * 2018-10-22 2022-07-27 International AIDS Vaccine Initiative Anticorps anti-vih
TWI878355B (zh) * 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
KR20220162690A (ko) * 2020-01-31 2022-12-08 젠선 바이오파마, 인코포레이티드 이중특이성 t 세포 관여항체
CA3173587A1 (fr) * 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Molecules multispecifiques de liaison a l'antigene ciblant dll3 et leurs utilisations
CA3180665A1 (fr) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Molecules de liaison pour le traitement du cancer
EP4153625A4 (fr) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York Anticorps neutralisants puissants contre le sras-cov-2, leur génération et leurs utilisations
CN111551733A (zh) * 2020-05-29 2020-08-18 武汉大学 定量检测免疫细胞来源细胞外囊泡pd-1含量的方法、elisa试剂盒及使用方法
WO2022060901A1 (fr) 2020-09-16 2022-03-24 Amgen Inc. Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer
EP4240755A4 (fr) * 2020-11-06 2024-12-18 Board of Regents, The University of Texas System Méthodes et compositions de classification et de traitement du cancer du poumon à petites cellules
WO2022153194A1 (fr) * 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-dérivé de pyrrolobenzodiazépine
WO2022153195A1 (fr) * 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-médicament anti-dll3
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2022237647A1 (fr) * 2021-05-08 2022-11-17 上海齐鲁制药研究中心有限公司 Molécule de liaison contre dll3 et son utilisation
KR20240006585A (ko) * 2021-05-10 2024-01-15 암젠 인크 Dll3 및 pd-1을 표적으로 하는 병용 요법을 위한 투여 요법
TW202317625A (zh) * 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
CN118076878A (zh) 2021-09-02 2024-05-24 勃林格殷格翰国际公司 确定未来颜色值或相应属性及其装置的方法
EP4454662A4 (fr) * 2021-12-23 2025-04-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticorps anti-dll3 et son utilisation pharmaceutique, et conjugué anticorps-médicament contenant un anticorps anti-dll3
KR20240141178A (ko) * 2022-02-10 2024-09-25 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 이중특이적 항원-결합 분자 및 이의 용도
KR20240153575A (ko) 2022-02-23 2024-10-23 암젠 인크 Dll3을 표적화하는 암 치료
EP4545564A4 (fr) * 2022-06-23 2026-01-14 Jiangsu Hengrui Pharmaceuticals Co Ltd Molécule de liaison à l'antigène se liant spécifiquement à dll3 et cd3, et son utilisation pharmaceutique
KR20250091261A (ko) 2022-10-26 2025-06-20 베링거 인겔하임 인터내셔날 게엠베하 Sting를 활성화할 수 있는 헤테로사이클릭 화합물
TW202432545A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
TW202432115A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins
CN120303300A (zh) * 2022-12-08 2025-07-11 安进公司 治疗表达dll3的癌症的方法
US20240352102A1 (en) * 2023-01-27 2024-10-24 The United States Government As Represented By The Department Of Veterans Affairs Compositions for treating tauopathies and methods of use thereof
WO2024179470A1 (fr) 2023-02-27 2024-09-06 苏州盛迪亚生物医药有限公司 Anticorps anti-dll3, conjugué anticorps-médicament et son utilisation pharmaceutique
CN121620371A (zh) 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途
TW202539735A (zh) * 2023-12-22 2025-10-16 大陸商江蘇恆瑞醫藥股份有限公司 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
WO2025146127A1 (fr) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 Anticorps bispécifique dirigé contre dll3 et cd3 et utilisation d'anticorps bispécifique
TW202600597A (zh) * 2024-03-04 2026-01-01 加拿大商酵活英屬哥倫比亞有限公司 靶向ｄｌｌ３之三特異性抗體構築體及其使用方法
WO2025193578A1 (fr) 2024-03-11 2025-09-18 Amgen Inc. Méthode de traitement de métastases cérébrales chez des sujets atteints d'un cancer dll3-positif
WO2025217101A2 (fr) 2024-04-09 2025-10-16 Amgen Inc. Anticorps agonistes à chaîne lourde anti-il-2rbg
WO2026059931A2 (fr) * 2024-09-11 2026-03-19 Telix Targeting Technologies, Inc. Constructions de liaison à l'antigène de dll3
WO2026060304A1 (fr) 2024-09-13 2026-03-19 Amgen Inc. Administration sous-cutanée d'un agent anti-dll3 pour le traitement du cancer
WO2026075950A1 (fr) 2024-10-01 2026-04-09 Amgen Inc. Schéma posologique pour agent anti-dll3

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
EP0826696B1 (fr) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Utilisation des anticorps bi- et trispécifiques pour induire une immunité antitumorale
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
WO2003092043A2 (fr) 2001-07-20 2003-11-06 Quantum Dot Corporation Nanoparticules luminescentes et techniques de preparation
EP1638510B1 (fr) 2003-07-01 2015-09-02 Immunomedics, Inc. Porteuses polyvalentes d'anticorps bispecifiques
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
JP5686953B2 (ja) * 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
CA2633593A1 (fr) 2005-12-16 2007-10-04 Genentech, Inc. Methode de diagnostic, de pronostic et de traitement du gliome
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP3736338A1 (fr) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Purification améliorée d'une protéine grâce à une élution modifiée de la protéine a
WO2011075861A1 (fr) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Procédé pour faire baisser l'immunogénicité
EP3907242A1 (fr) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-dll3
US8916162B2 (en) 2010-02-20 2014-12-23 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA3051311A1 (fr) 2010-05-27 2011-12-01 Genmab A/S Anticorps monoclonaux contre her2
CA2806252C (fr) 2010-07-29 2019-05-14 Xencor, Inc. Anticorps dont les points isoelectriques sont modifies
WO2012106578A1 (fr) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisant le vih, présentant des mutations dans le domaine constant (fc)
CA2827188C (fr) 2011-03-17 2020-02-11 Ramot At Tel-Aviv University Ltd. Anticorps asymetriques bi- et monospecifiques et leur procede de generation
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
WO2012143523A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
HRP20240230T1 (hr) 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
PT2794905T (pt) * 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
RU2014138474A (ru) * 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
CA2878587A1 (fr) * 2012-07-23 2014-01-30 Zymeworks Inc. Constructions d'immunoglobuline comprenant un appariement selectif des chaines legere et lourde
US20150016666A1 (en) 2012-11-02 2015-01-15 Google Inc. Method and Apparatus for Determining Geolocation of Image Contents
EP3878964A1 (fr) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Paire de variants du domaine ch3 induisant la formation d'hétérodimère de région constante de chaîne lourde d'anticorps à haute efficacité, procédé de préparation associé et utilisation associée
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
HK1220919A1 (zh) 2013-04-05 2017-05-19 F. Hoffmann-La Roche Ag 抗il-4抗体和双特异性抗体及其用途
EP2992010B1 (fr) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Anticorps asymétrique modifié de liaison fc-receptor et procédés d'utilisation
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MX379030B (es) * 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
HRP20231139T1 (hr) 2014-05-06 2024-01-05 F. Hoffmann - La Roche Ag Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
WO2016014974A2 (fr) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps
WO2016016415A1 (fr) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Construction d'anticorps monocaténaires bispécifiques avec distribution tissulaire améliorée
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
AR101753A1 (es) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
WO2016071377A1 (fr) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Variants de région fc présentant des propriétés modifiées de liaison à fcrn et à la protéine a
AU2016285858A1 (en) * 2015-06-30 2017-11-30 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
WO2017030926A1 (fr) * 2015-08-17 2017-02-23 Macrogenics, Inc. Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations
UA127200C2 (uk) 2016-05-18 2023-06-07 Бьорінгер Інгельхайм Інтернаціональ Гмбх Молекула антитіла до pd1
EP3732195A4 (fr) * 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique induisant une cytotoxicité
IL277863B2 (en) * 2018-04-11 2026-02-01 Inhibrx Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
KR102839606B1 (ko) 2018-12-31 2025-07-29 삼성디스플레이 주식회사 색변환 기판 및 표시 장치
WO2022201053A1 (fr) * 2021-03-24 2022-09-29 Janssen Biotech, Inc. Protéines comprenant des domaines de liaison à l'antigène cd3 et leurs utilisations

Also Published As

Publication number Publication date
JP2021526816A (ja) 2021-10-11
TW202016151A (zh) 2020-05-01
US20220251236A1 (en) 2022-08-11
CL2020003105A1 (es) 2021-06-11
CN119285788A (zh) 2025-01-10
EP3802598B1 (fr) 2025-02-12
MX2020013348A (es) 2021-03-09
CN119499365A (zh) 2025-02-25
PE20210321A1 (es) 2021-02-16
HUE071620T2 (hu) 2025-09-28
JP7133043B2 (ja) 2022-09-07
EP3802598A1 (fr) 2021-04-14
HRP20250443T1 (hr) 2025-06-06
PL3802598T3 (pl) 2025-06-09
JOP20200313A1 (ar) 2020-12-06
AU2019280900B2 (en) 2026-02-19
IL279235A (en) 2021-01-31
US20230295337A1 (en) 2023-09-21
FI3802598T3 (fi) 2025-03-18
BR112020022898A2 (pt) 2021-02-23
CN119490599A (zh) 2025-02-21
US20190375849A1 (en) 2019-12-12
US12528879B2 (en) 2026-01-20
SA520420748B1 (ar) 2023-12-06
CN119241717A (zh) 2025-01-03
LT3802598T (lt) 2025-04-10
PH12020552080A1 (en) 2021-05-31
CN120131936A (zh) 2025-06-13
DK3802598T3 (da) 2025-03-31
SG11202011134XA (en) 2020-12-30
TWI848953B (zh) 2024-07-21
EP4566621A3 (fr) 2025-08-20
JP2022180379A (ja) 2022-12-06
CO2020015172A2 (es) 2020-12-21
CN119529097A (zh) 2025-02-28
MA52742B1 (fr) 2025-03-28
CN112513092B (zh) 2024-11-08
RS66693B1 (sr) 2025-05-30
WO2019234220A1 (fr) 2019-12-12
CA3099956A1 (fr) 2019-12-12
CN112513092A (zh) 2021-03-16
AU2019280900A1 (en) 2020-11-19
ECSP20084864A (es) 2021-05-31
IL279235B1 (en) 2026-05-01
US12173083B2 (en) 2024-12-24
MY199655A (en) 2023-11-14
ES3021463T3 (en) 2025-05-27
SI3802598T1 (sl) 2025-08-29
KR20210018311A (ko) 2021-02-17
EP4566621A2 (fr) 2025-06-11
US11332541B2 (en) 2022-05-17
CR20200601A (es) 2021-01-26

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3941944A4 (fr) Anticorps de claudin-6 bispécifiques
EP3507307A4 (fr) Anticorps bispécifiques
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3763743A4 (fr) Anticorps bispécifique
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3885367A4 (fr) Anticorps bispécifique anti-her2/pd1
EP3752536A4 (fr) Anticorps anti-her2
MA52152A (fr) Anticorps
DK3504241T3 (da) Anti-cd3-antistofformuleringer
MA55705A (fr) Anticorps bispécifiques
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3831851A4 (fr) Anticorps anti-btla
EP3746120A4 (fr) Anticorps anti-pd-1
MA51134A (fr) Anticorps anti-alpha-synucléine
MA49250A (fr) Nouveaux anticorps anti-cd3
MA56466A (fr) Anticorps anti-epha4
EP3626745A4 (fr) Anticorps bispécifique recombinant